ipn01194

IPN01194 is an investigational small molecule drug developed as an ERK1/2 inhibitor, targeting the MAPK pathway, which is frequently mutated and overactive in various advanced solid tumors. By inhibiting ERK1/2 proteins, IPN01194 aims to disrupt cancer cell growth and proliferation. It is currently being evaluated in first-in-human Phase I/IIa clinical trials for its safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity in adults with advanced solid tumors—including melanoma, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer, and other malignancies with MAPK pathway mutations. The drug is administered orally as a hard capsule[1][3][5][7].